We propose to apply methods of molecular biology to the study of the genetic disorders known as Mucopolysaccharidosis I (MPS I). These include the Hurler, Hurler/Scheie and Scheie syndromes, as well as a canine disease analogous to Hurler/Scheie. All forms of MPS I are caused by lack of activity of the lysosomal enzyme alpha-L-iduronidase. Our goal is two-fold: (1) to characterize precisely the mutation that give rise to human and canine MPS I and (2) to attempt therapy of the canine disease by genetic modification of bone marrow cells. The rationale for the therapeutic trial is the prior demonstration that canine MPS I responds biochemically and clinically to allogeneic bone marrow transplantation. Cloned cDNA encoding the alpha-L-iduronidase is required for both purposes. We shall purify the enzyme to homogeneity, screen lambda GT11 libraries (human and canine) with antisera and/or oligonucleotide probes, characterize and sequence the cDNA. Using biosynthetic radiolabeling in cell culture, we shall determine if cells from MPS I patients are able to synthesize and process cross-reactive protein; if not, we shall determine by Southern and Northern hybridization and nuclear run-on transcription whether the alpha-L-iduronidase gene is intact and transcribed. We plan to localize precisely to the genomic sequence those mutations deemed most informative. We will express full-length alpha-L-iduronidase cDNA in MPS I cells, using a retroviral delivery system of the type described by Mulligan and colleagues. Once expression (i.e., appearance of intralysosomal a-L-iduronidase activity) has been demonstrated in fibroblasts and hematopoietic cells, we will proceed to expression in vivo. Bone marrow will be collected from MPS I dogs, enriched in stem cells, infected with the retrovirus containing the alpha-L- iduronidase cDNA and returned to the donors. Integration and expression of the cDNA will be monitored in circulating leukocytes. After a pilot feasibility experiment, the protocol will be modeled on the recent bone marrow transplantation studies. Four to six MPS I dogs, prepared by irradiation or chemotherapeutic drugs, will be treated with their own genetically modified bone marrow. They will be compared with untreated affected and normal controls with respect to biochemical, ultrastructural and clinical parameters, in order to determine the long term consequences of such genetic therapy.

National Institute of Health (NIH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Research Project (R01)
Project #
Application #
Study Section
Mammalian Genetics Study Section (MGN)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California Los Angeles
Schools of Medicine
Los Angeles
United States
Zip Code
Jordan, Maria C; Zheng, Yi; Ryazantsev, Sergey et al. (2005) Cardiac manifestations in the mouse model of mucopolysaccharidosis I. Mol Genet Metab 86:233-43
Ohmi, Kazuhiro; Greenberg, David S; Rajavel, Kavitha S et al. (2003) Activated microglia in cortex of mouse models of mucopolysaccharidoses I and IIIB. Proc Natl Acad Sci U S A 100:1902-7
Zhao, K W; Faull, K F; Kakkis, E D et al. (1997) Carbohydrate structures of recombinant human alpha-L-iduronidase secreted by Chinese hamster ovary cells. J Biol Chem 272:22758-65
Shull, R M; Lu, X; McEntee, M F et al. (1996) Myoblast gene therapy in canine mucopolysaccharidosis. I: Abrogation by an immune response to alpha-L-iduronidase. Hum Gene Ther 7:1595-603
Kakkis, E D; McEntee, M F; Schmidtchen, A et al. (1996) Long-term and high-dose trials of enzyme replacement therapy in the canine model of mucopolysaccharidosis I. Biochem Mol Med 58:156-67
Tieu, P T; Bach, G; Matynia, A et al. (1995) Four novel mutations underlying mild or intermediate forms of alpha-L-iduronidase deficiency (MPS IS and MPS IH/S). Hum Mutat 6:55-9
Menon, K P; Neufeld, E F (1994) Evidence for degradation of mRNA encoding alpha-L-iduronidase in Hurler fibroblasts with premature termination alleles. Cell Mol Biol (Noisy-le-grand) 40:999-1005
Kakkis, E D; Matynia, A; Jonas, A J et al. (1994) Overexpression of the human lysosomal enzyme alpha-L-iduronidase in Chinese hamster ovary cells. Protein Expr Purif 5:225-32
Shull, R M; Kakkis, E D; McEntee, M F et al. (1994) Enzyme replacement in a canine model of Hurler syndrome. Proc Natl Acad Sci U S A 91:12937-41
Tieu, P T; Menon, K; Neufeld, E F (1994) A mutant stop codon (TAG) in the IDUA gene is used as an acceptor splice site in a patient with Hurler syndrome (MPS IH). Hum Mutat 3:333-6

Showing the most recent 10 out of 22 publications